Skip to main content
PMC home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1984 Jan;17(1):67–75. doi: 10.1111/j.1365-2125.1984.tb05001.x

Effects of migraine attack and metoclopramide on the absorption of tolfenamic acid.

R A Tokola, P J Neuvonen
PMCID: PMC1463294  PMID: 6691890

Abstract

The effect of acute migraine attack and rectally given metoclopramide on the absorption of orally given tolfenamic acid (300 mg) was investigated in seven female patients in a crossover study consisting of four phases, two without migraine and two during migraine. Metoclopramide hydrochloride (20 mg) or placebo was given double-blind. Migraine attacks delayed the absorption of tolfenamic acid. Serum concentrations of tolfenamic acid 1.5 and 2 h after drug administration remained smaller, the peak serum concentration (tmax) occurred later and the area under the serum concentration-time curve between zero and 2 h (AUC0-2 h) remained decreased during migraine. Metoclopramide pretreatment in migraine attacks increased the serum concentration of tolfenamic acid at 1.5 h, but its peak concentration, time to peak concentration and the AUC0-5 h remained unchanged as compared with the values obtained with tolfenamic acid alone. Between the absorption of tolfenamic acid without migraine and after metoclopramide pretreatment during migraine no significant differences existed. When the patients were studied without migraine the serum concentrations of tolfenamic acid 45 min and 60 min after its administration were higher after metoclopramide than after placebo pretreatment. During migraine attacks the serum concentrations and the AUC0-5.5 h of metoclopramide were slightly lowered. The impairment of drug absorption by migraine was not related to the duration or severity of the attack. The observed changes in drug absorption during migraine attacks are obviously due to the delay in gastric emptying. Rectally administered metoclopramide accelerates the absorption of orally given tolfenamic acid.

Full text

PDF
70

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ala-Hurula V., Myllylä V. V., Hokkanen E., Tokola O. Tolfenamic acid and ergotamine abuse. Headache. 1981 Nov;21(6):240–242. doi: 10.1111/j.1526-4610.1981.hed2106240.x. [DOI] [PubMed] [Google Scholar]
  2. Anthony M. Biochemical indices of sympathetic activity in migraine. Cephalalgia. 1981 Jun;1(2):83–89. doi: 10.1111/j.1468-2982.1981.tb00014.x. [DOI] [PubMed] [Google Scholar]
  3. Curran D. A., Hinterberger H., Lance J. W. Total plasma serotonin, 5-hydroxyindoleacetic acid and p-hydroxy-m-methoxymandelic acid excretion in normal and migrainous subjects. Brain. 1965 Dec;88(5):997–1010. doi: 10.1093/brain/88.5.997. [DOI] [PubMed] [Google Scholar]
  4. Graffner C., Lagerström P. O., Lundborg P., Rönn O. Pharmacokinetics of metoclopramide intravenously and orally determined by liquid chromatography. Br J Clin Pharmacol. 1979 Nov;8(5):469–474. doi: 10.1111/j.1365-2125.1979.tb01028.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Hakkarainen H., Parantainen J., Gothoni G., Vapaatalo H. Tolfenamic acid and caffeine: a useful combination in migraine. Cephalalgia. 1982 Dec;2(4):173–177. doi: 10.1046/j.1468-2982.1982.0204173.x. [DOI] [PubMed] [Google Scholar]
  6. Hakkarainen H., Vapaatalo H., Gothoni G., Parantainen J. Tolfenamic acid is as effective as ergotamine during migraine attacks. Lancet. 1979 Aug 18;2(8138):326–328. doi: 10.1016/s0140-6736(79)90343-x. [DOI] [PubMed] [Google Scholar]
  7. Harrington R. A., Hamilton C. W., Brogden R. N., Linkewich J. A., Romankiewicz J. A., Heel R. C. Metoclopramide. An updated review of its pharmacological properties and clinical use. Drugs. 1983 May;25(5):451–494. doi: 10.2165/00003495-198325050-00002. [DOI] [PubMed] [Google Scholar]
  8. Joyce C. R., Zutshi D. W., Hrubes V., Mason R. M. Comparison of fixed interval and visual analogue scales for rating chronic pain. Eur J Clin Pharmacol. 1975 Aug 14;8(6):415–420. doi: 10.1007/BF00562315. [DOI] [PubMed] [Google Scholar]
  9. Lance J. W., Anthony M., Hinterberger H. The control of cranial arteries by humoral mechanisms and its relation to the migraine syndrome. Headache. 1967 Oct;7(3):93–102. doi: 10.1111/j.1526-4610.1967.hed0703134.x. [DOI] [PubMed] [Google Scholar]
  10. Lindén I. B., Parantainen J., Vapaatalo H. Inhibition of prostaglandin biosynthesis by tolfenamic acid in vitro. Scand J Rheumatol. 1976;5(3):129–132. doi: 10.3109/03009747609165450. [DOI] [PubMed] [Google Scholar]
  11. Malagelada J. R. Gastric emptying disorders. Clinical significance and treatment. Drugs. 1982 Nov;24(5):353–359. doi: 10.2165/00003495-198224050-00001. [DOI] [PubMed] [Google Scholar]
  12. Manninen V., Apajalahti A., Melin J., Karesoja M. Altered absorption of digoxin in patients given propantheline and metoclopramide. Lancet. 1973 Feb 24;1(7800):398–400. doi: 10.1016/s0140-6736(73)90252-3. [DOI] [PubMed] [Google Scholar]
  13. Mathew R. J., Ho B. T., Kralik P., Taylor D., Claghorn J. L. Catecholamines and migraine: evidence based on biofeedback induced changes. Headache. 1980 Sep;20(5):247–252. doi: 10.1111/j.1526-4610.1980.hed2005247.x. [DOI] [PubMed] [Google Scholar]
  14. Maxwell C. Sensitivity and accuracy of the visual analogue scale: a psycho-physical classroom experiment. Br J Clin Pharmacol. 1978 Jul;6(1):15–24. doi: 10.1111/j.1365-2125.1978.tb01676.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Mearrick P. T., Wade D. N., Birkett D. J., Morris J. Metoclopramide, gastric emptying and L-dopa absorption. Aust N Z J Med. 1974 Apr;4(2):144–148. doi: 10.1111/j.1445-5994.1974.tb03163.x. [DOI] [PubMed] [Google Scholar]
  16. Nimmo W. S. Drugs, diseases and altered gastric emptying. Clin Pharmacokinet. 1976;1(3):189–203. doi: 10.2165/00003088-197601030-00002. [DOI] [PubMed] [Google Scholar]
  17. Pentikäinen P. J., Neuvonen P. J., Backman C. Human pharmacokinetics of tolfenamic acid, a new anti-inflammatory agent. Eur J Clin Pharmacol. 1981;19(5):359–365. doi: 10.1007/BF00544587. [DOI] [PubMed] [Google Scholar]
  18. Pinder R. M., Brogden R. N., Sawyer P. R., Speight T. M., Avery G. S. Metoclopramide: a review of its pharmacological properties and clinical use. Drugs. 1976;12(2):81–131. doi: 10.2165/00003495-197612020-00001. [DOI] [PubMed] [Google Scholar]
  19. Rees M. R., Clark R. A., Holdsworth C. D., Barber D. C., Howlett P. J. The effect of beta-adrenoceptor agonists and antagonists on gastric emptying in man. Br J Clin Pharmacol. 1980 Dec;10(6):551–554. doi: 10.1111/j.1365-2125.1980.tb00509.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Ross-Lee L., Heazlewood V., Tyrer J. H., Eadie M. J. Aspirin treatment of migraine attacks: plasma drug level data. Cephalalgia. 1982 Mar;2(1):9–14. doi: 10.1046/j.1468-2982.1982.0201009.x. [DOI] [PubMed] [Google Scholar]
  21. Schulze-Delrieu K. Drug therapy. Metoclopramide. N Engl J Med. 1981 Jul 2;305(1):28–33. doi: 10.1056/NEJM198107023050106. [DOI] [PubMed] [Google Scholar]
  22. Tokola R. A., Anttila V. J., Neuvonen P. J. The effect of metoclopramide on the absorption of tolfenamic acid. Int J Clin Pharmacol Ther Toxicol. 1982 Oct;20(10):465–468. [PubMed] [Google Scholar]
  23. Volans G. N. Absorption of effervescent aspirin during migraine. Br Med J. 1974 Nov 2;4(5939):265–268. doi: 10.1136/bmj.4.5939.265. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Volans G. N. Migraine and drug absorption. Clin Pharmacokinet. 1978 Jul-Aug;3(4):313–318. doi: 10.2165/00003088-197803040-00004. [DOI] [PubMed] [Google Scholar]
  25. Volans G. N. The effect of metoclopramide on the absorption of effervescent aspirin in migraine. Br J Clin Pharmacol. 1975 Feb;2(1):57–63. doi: 10.1111/j.1365-2125.1975.tb00472.x. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES